{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:27:39Z","timestamp":1791235659345,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Society of Clinical Oncology Educational Book"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Precision medicine changes the landscape of oncology practices by offering the opportunity to optimize care through a more targeted, personalized approach of managing cancer treatments. However, precision oncology is costly and does not benefit all patients with cancer, making it critically important to consider the tradeoff between costs and health benefits. Here, we discuss the global challenges in implementing precision oncology from the perspective of health care management and health economics and emphasize the different challenges for high-income compared with low- and middle-income countries. For health care managers making resource allocation decisions, the decision to adopt, implement, and finance precision oncology must consider opportunity costs, and the allocation must be proportional to the system\u2019s capacity. The standard approach of health technology assessment is inadequate because it fails to consider the capacity to pay. From an economic perspective, global implementation of precision oncology must confront the issues of accessibility, affordability, and system readiness. Low- and middle-income countries often have no or delayed access to novel targeted-therapy agents, find these drugs cost-prohibitive, and struggle to build the infrastructure with sufficient workforce and adequate testing and computing facilities to capitalize the benefit of precision oncology. Although high-income countries are better equipped to implement precision oncology, the challenges there lie in implementing strategies to maximize the value of precision oncology through promoting appropriate use while limiting inappropriate applications. The recent rollout of COVID-19 vaccines internationally highlights the importance of information uncertainty and offers valuable insights on global access to and implementation of precision oncology.<\/jats:p>","DOI":"10.1200\/edbk_359650","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T15:59:30Z","timestamp":1652803170000},"page":"429-437","source":"Crossref","is-referenced-by-count":28,"title":["Global Challenges in Access to and Implementation of Precision Oncology: The\u00a0Health Care Manager and Health\u00a0Economist\u00a0Perspective"],"prefix":"10.1200","author":[{"given":"Ya-Chen Tina","family":"Shih","sequence":"first","affiliation":[{"name":"Section of Cancer Economics and Policy, Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Wen","family":"Pan","sequence":"additional","affiliation":[{"name":"Section of Cancer Economics and Policy, Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Teich","sequence":"additional","affiliation":[{"name":"Brazil Governance Network, Bras\u00edlia, Federal District, Brazil"},{"name":"4D PATH, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"bibr1-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6987"},{"key":"bibr2-EDBK_359650","volume-title":"Drug Expenditure Dynamics 1995\u20132020: Understanding Medicine Spending in Context","author":"IQVIA","year":"2021"},{"key":"bibr3-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70141-3"},{"key":"bibr4-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0054"},{"key":"bibr5-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2265"},{"key":"bibr6-EDBK_359650","unstructured":"IQVIA.\n                      Global Oncology Trends 2021. Outlook to 2025\n                      . Danbury, CT: IQVIA Institute for Human Data Science; 2021."},{"key":"bibr7-EDBK_359650","volume-title":"Global Oncology Trends 2019. Therapeutics, Clinical Development and Health System Implications","author":"IQVIA","year":"2019"},{"key":"bibr8-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00463-0"},{"key":"bibr9-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13375-2"},{"key":"bibr10-EDBK_359650","volume-title":"World Health Organization Model List of Essential Medicines \u2013 22nd List, 2021","author":"World Health Organization","year":"2021"},{"key":"bibr11-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1080\/20502877.2017.1314885"},{"key":"bibr12-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1345"},{"key":"bibr13-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw205"},{"key":"bibr16-EDBK_359650","volume-title":"Brazil Pharmaceuticals & Healthcare Report"},{"key":"bibr17-EDBK_359650","first-page":"13","volume-title":"Health Aff (Millwood)","volume":"41","author":"Health Expenditure Accounts Team","year":"2022"},{"key":"bibr19-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17742"},{"key":"bibr20-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30750-6"},{"key":"bibr21-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.07.049403"},{"key":"bibr22-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.06.022"},{"key":"bibr23-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.011"},{"key":"bibr24-EDBK_359650","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond MF","year":"2015","edition":"4"},{"key":"bibr25-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197507312930502"},{"key":"bibr26-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197703312961304"},{"key":"bibr27-EDBK_359650","first-page":"1","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond MF","year":"2015","edition":"4"},{"key":"bibr28-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_174176"},{"key":"bibr30-EDBK_359650","first-page":"1211","volume":"83","author":"Bresiz E","year":"1993","journal-title":"Am Econ Rev"},{"key":"bibr31-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00346"},{"key":"bibr32-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.920"},{"key":"bibr33-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.2217\/pme-2017-0055"},{"key":"bibr34-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.759"},{"key":"bibr35-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02288-1"},{"key":"bibr36-EDBK_359650","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02183-8"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK_359650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T11:12:52Z","timestamp":1683285172000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_359650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":32,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1200\/EDBK_359650"],"URL":"https:\/\/doi.org\/10.1200\/edbk_359650","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}